Answering the narrow version, because the broad one does not have a single answer. ApoB is the more informative number and it is cheap. LDL-C estimates cholesterol mass in atherogenic particles; ApoB counts the particles, and it is particle count that tracks risk — which is why the two can disagree and why the disagreement is the clinically interesting case. Triglycerides fall substantially with weight loss and improved insulin sensitivity, HDL moves modestly, and LDL-C often barely moves at all, which surprises people who expected everything to improve together.

NeuroNate said:

ApoB is the more informative number and it is cheap.

Agreed, and hsCRP is worth reading alongside them. The inflammatory-marker fall is often the most striking change on a panel and it is consistent with the cardiovascular outcome data.

That is the short version; the long version is somebody else's post.

rachel_ABQ said:

One order arrived in nine days, one was held at the border for a fortnight, and one came back with a seizure notice.

Second this. I had assumed I was the exception until I read this.

Adding the clinical framing, because it changes how the question reads.

My experience ordering cross-border ordering internationally: I've ordered from an Australian compounder. Customs can be hit or miss.

Shipping time: 5-10 days
Customs clearance: was seized once, reshipped free
Quality: Janoshik tested at 98.4% purity

International ordering adds complexity but can save 60-80% compared to US prices. Research your country's import laws first.